15 Jul 2024
// PRESS RELEASE
24 Jun 2024
// PRESS RELEASE
10 May 2024
// PRESS RELEASE
AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
About
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Attending
14-18 July, 2025
ChemOutsourcingChemOutsourcing
Industry Trade Show
Attending
08-10 September, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Attending
14-18 July, 2025
ChemOutsourcingChemOutsourcing
Industry Trade Show
Attending
08-10 September, 2025
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities
https://www.pharmacompass.com/radio-compass-blog/ophthalmic-dealmakers-novartis-abbvie-forge-deals-to-develop-ocular-gene-therapies
15 Jul 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/success-factors-for-pre-filled-syringe-cmo-selection.html
24 Jun 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/how-abbvie-operations-and-contract-manufacturing-has-prepared-global-parenteral-sites-for-the-annex-1-compliance-requirement.html
10 May 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/translating-environmental-social-and-governance-esg-benefits-to-our-partners.html
20 Mar 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/AbbVie-Contract-Manufacturing-12-Time-CMO-Leadership-Award-Winner.html#:~:text=AbbVie%20Contract%20Manufacturing%20%E2%80%93%2012%2DTime%20CMO%20Leadership%20Award%20Winner&text=AbbVie%20Contract%20Manufacturing%20has%20been,industry%20research%20and%20customer%20surveys.
11 Mar 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/abbvie-contract-manufacturing-recognized-by-life-science-leader-for-the-11th-year.html
18 Jan 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/Four-Myths-About-Embedded-CMOs-Busted.html
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN HP
Dosage Strength : 660MG;10MG
Approval Date : 1996-09-23
Application Number : 40117
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN
Dosage Strength : 500MG;5MG
Approval Date : 1983-01-07
Application Number : 88058
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN ES
Dosage Strength : 750MG;7.5MG
Approval Date : 1988-12-09
Application Number : 89736
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : ACYCLOVIR
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 1999-07-26
Application Number : 75114
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD :
TE Code :
Dosage Form : SYRINGE
Proprietary Name : HUMIRA
Dosage Strength : 40MG/0.8ML
Approval Date :
Application Number : 125057
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : VIAL
Proprietary Name : HUMIRA
Dosage Strength : 40MG/0.8ML
Approval Date :
Application Number : 125057
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Dosage Form : SOLUTION/DROPS; OPHTHALMIC
Proprietary Name : LASTACAFT
Dosage Strength : 0.25%
Approval Date : 2010-07-28
Application Number : 22134
RX/OTC/DISCN : OTC
RLD : Yes
TE Code :
RLD : Yes
TE Code : AB
Dosage Form : TABLET; SUBLINGUAL
Proprietary Name : SAPHRIS
Dosage Strength : EQ 5MG BASE
Approval Date : 2009-08-13
Application Number : 22117
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : Yes
TE Code : AB
Dosage Form : TABLET; SUBLINGUAL
Proprietary Name : SAPHRIS
Dosage Strength : EQ 10MG BASE
Approval Date : 2009-08-13
Application Number : 22117
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : Yes
TE Code : AB
Dosage Form : TABLET; SUBLINGUAL
Proprietary Name : SAPHRIS
Dosage Strength : EQ 2.5MG BASE
Approval Date : 2015-03-12
Application Number : 22117
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Services
API Manufacturing
Drug Product Manufacturing
API & Drug Product Development
Packaging
Inspections and registrations
ABOUT THIS PAGE